Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are coping, thank you, despite the ongoing calamity engulfing all of us these days. We are keeping busy with our usual routine of phone calls, deadlines, and foraging for interesting items. In other words, we remain productively distracted. Hopefully you are as well. Meanwhile, please join us for a cup of stimulation as we get cracking. Hope your day is manageable and, most of all, safe. And please do keep in touch.

The world will need more than one Covid-19 vaccine so drug companies must partner in the race to develop the weapons to fight the novel coronavirus, GlaxoSmithKline (GSK) chief executive officer Emma Walmsley tells Reuters. GSK and Sanofi (SNY) plan to develop a vaccine to fight the fast-spreading coronavirus. The drug makers expect to start clinical trials for the vaccine in the second half of this year and, if successful, the vaccine would be available in the second half of 2021.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.